Medivation Inc (MDVN) : Tudor Investment Corp Et Al scooped up 534,125 additional shares in Medivation Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 661,185 shares of Medivation Inc which is valued at $43,651,434.Medivation Inc makes up approximately 1.67% of Tudor Investment Corp Et Al’s portfolio.
Other Hedge Funds, Including , Weiss Multi-strategy Advisers reduced its stake in MDVN by selling 2,000 shares or 2.5% in the most recent quarter. The Hedge Fund company now holds 78,000 shares of MDVN which is valued at $5,149,560. Medivation Inc makes up approx 0.23% of Weiss Multi-strategy Advisers’s portfolio.Raymond James Associates boosted its stake in MDVN in the latest quarter, The investment management firm added 9,587 additional shares and now holds a total of 15,599 shares of Medivation Inc which is valued at $1,029,846.Swiss National Bank boosted its stake in MDVN in the latest quarter, The investment management firm added 35,100 additional shares and now holds a total of 460,400 shares of Medivation Inc which is valued at $29,502,432. Medivation Inc makes up approx 0.05% of Swiss National Bank’s portfolio.California State Teachers Retirement System boosted its stake in MDVN in the latest quarter, The investment management firm added 2,822 additional shares and now holds a total of 337,180 shares of Medivation Inc which is valued at $21,606,494. Medivation Inc makes up approx 0.05% of California State Teachers Retirement System’s portfolio.
Medivation Inc opened for trading at $80.45 and hit $80.98 on the upside on Thursday, eventually ending the session at $80.93, with a gain of 0.46% or 0.37 points. The heightened volatility saw the trading volume jump to 67,00,788 shares. Company has a market cap of $13,429 M.
On the company’s financial health, Medivation Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.26. The company had revenue of $206.20 million for the quarter, compared to analysts expectations of $209.92 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 EPS.
Many Wall Street Analysts have commented on Medivation Inc. Medivation Inc was Downgraded by Stifel to ” Hold” on Aug 23, 2016. Medivation Inc was Downgraded by Credit Suisse to ” Neutral” on Aug 23, 2016. Company shares were Downgraded by Maxim Group on Aug 23, 2016 to ” Hold”, Firm has raised the Price Target to $ 81.50 from a previous price target of $76 .
Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.